

REMARKS

Claims 9-11 and 29-31 are pending in this application. The claims are as originally filed. The amendment is made to place the application in condition for allowance and does not provoke a new examination. Entry of the amendment is requested.

Claims 9-11 and 29-31 have been indicated to be allowed. Applicant wish to point out that the acceptance of the allowance is for reasons related to the commercialization of the invention. It does not mean that Applicant acquiesced in the restriction of the application to the finding of patentability of SEQ ID NO:51. The present invention is directed to a peptide that is suitable as an immunogen for eliciting antibodies that are immunoreactive with the A β ₁₋₄₂ peptide and the amyloid plaques deposited in the brains of Alzheimer patients. And because the antibodies generated have such immunoreactivity, the peptide immunogens are useful for the treatment of Alzheimer condition.

The patentability of the claimed peptide immunogens and the method of use and method treatment are not to be limited only to a review of whether the Th epitopes that are conjugated to the N-terminal fragment of the A β ₁₋₄₂ peptide as claimed. Applicant is filing concurrently a divisional application directed to the invention of claims 1-8, 12-18 and 32-80 which were cancelled from the present application.

Applicant also wishes to thank the Examiner and her supervisor, Mr. Gary Kunz for their efforts in moving the application through the examination process.

Respectfully Submitted,



Maria C.H. Lin
Registration No. 29,323

Date: June 4, 2004

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154
Tel: 212-758-4800
Fax: 212-751-6849
Direct Line: 212-415-8745